CLINICAL TRIALS PROFILE FOR DELGOCITINIB
✉ Email this page to a colleague
Clinical Trials for delgocitinib
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03683719 ↗ | Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema | Completed | LEO Pharma | Phase 2 | The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life. |
NCT03725722 ↗ | Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. | Completed | LEO Pharma | Phase 2 | This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD). |
NCT03826901 ↗ | Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children | Completed | LEO Pharma | Phase 1 | This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis. |
NCT03958955 ↗ | Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. | Terminated | LEO Pharma | Phase 2 | This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE). |
NCT04361136 ↗ | Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream | Completed | LEO Pharma | Phase 1 | This is a single-centre, randomised, vehicle-controlled, double-blind, within-subject comparison phase 1 clinical trial. The trial is designed to find out if delgocitinib cream can cause skin irritation after light exposure in people with healthy skin. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for delgocitinib
Condition Name
Clinical Trial Locations for delgocitinib
Trials by Country
Clinical Trial Progress for delgocitinib
Clinical Trial Phase
Clinical Trial Sponsors for delgocitinib
Sponsor Name